«Essential» phospholipids in diabetes mellitus. Review of the results all over the world
| Autor: | M. Kundurovich, K. Gundermann |
|---|---|
| Rok vydání: | 1994 |
| Předmět: | |
| Zdroj: | Problems of Endocrinology. 40:59-62 |
| ISSN: | 2308-1430 0375-9660 |
| Popis: | The purpose of the review is to evaluate the results obtained with the use of EPL (essential phospholipids) for the treatment of diabetes mellitus in the light of modern scientific knowledge, as well as to highlight the role of lipostabil in the treatment of diabetes mellitus. Since some studies did not set as their primary task the study of the effect of EPL on serum lipids and lipoproteins, and diabetes-specific parameters, such as blood glucose concentration, glycated hemoglobin (HbA1c), ketonemia, as well as possibilities, were put on the forefront. development of late complications (atherosclerotic vascular changes or retinopathy), then the evaluation of these studies was carried out in accordance with the measured parameters. The most important studies were analyzed. Since the beginning of the 90s, interest in the use of lipostabil in the treatment of diabetes has grown markedly. This interest was reflected in a double blind study by R. Kirsten et al., Completed in 1993. To date, there are data on 650 patients with insulin-dependent and non-insulin-dependent diabetes mellitus; one study is mainly related to diabetic retinopathy. The duration of therapy ranged from 14 days to 39 months, in most studies - several months. In some cases, lipostabil was used only orally, in others, simultaneously with intravenous administration, or therapy began with intravenous administration of the drug and continued with the use of oral capsules. The treatment of EPL was initially carried out on the background of only a diet, and then in combination with oral antidiabetic drugs or insulin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|